GB201717966D0 - Immunotoxins, formulations thereof and their use in medicine - Google Patents

Immunotoxins, formulations thereof and their use in medicine

Info

Publication number
GB201717966D0
GB201717966D0 GBGB1717966.4A GB201717966A GB201717966D0 GB 201717966 D0 GB201717966 D0 GB 201717966D0 GB 201717966 A GB201717966 A GB 201717966A GB 201717966 D0 GB201717966 D0 GB 201717966D0
Authority
GB
United Kingdom
Prior art keywords
immunotoxins
formulations
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1717966.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenikos Bv
Original Assignee
Xenikos Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenikos Bv filed Critical Xenikos Bv
Priority to GBGB1717966.4A priority Critical patent/GB201717966D0/en
Publication of GB201717966D0 publication Critical patent/GB201717966D0/en
Priority to CN201880084645.4A priority patent/CN111629753B/zh
Priority to CA3080873A priority patent/CA3080873A1/en
Priority to EP18803564.6A priority patent/EP3703748A1/en
Priority to PCT/EP2018/079860 priority patent/WO2019086534A1/en
Priority to JP2020543729A priority patent/JP7482343B2/ja
Priority to AU2018357984A priority patent/AU2018357984B2/en
Priority to US16/759,952 priority patent/US11447548B2/en
Priority to US17/816,550 priority patent/US12435138B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1717966.4A 2017-10-31 2017-10-31 Immunotoxins, formulations thereof and their use in medicine Ceased GB201717966D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1717966.4A GB201717966D0 (en) 2017-10-31 2017-10-31 Immunotoxins, formulations thereof and their use in medicine
CN201880084645.4A CN111629753B (zh) 2017-10-31 2018-10-31 免疫毒素、其制剂以及它们在药物中的用途
CA3080873A CA3080873A1 (en) 2017-10-31 2018-10-31 Immunotoxins, formulations thereof and their use in medicine
EP18803564.6A EP3703748A1 (en) 2017-10-31 2018-10-31 Immunotoxins, formulations thereof and their use in medicine
PCT/EP2018/079860 WO2019086534A1 (en) 2017-10-31 2018-10-31 Immunotoxins, formulations thereof and their use in medicine
JP2020543729A JP7482343B2 (ja) 2017-10-31 2018-10-31 免疫毒素、その製剤、および薬におけるその使用
AU2018357984A AU2018357984B2 (en) 2017-10-31 2018-10-31 Immunotoxins, formulations thereof and their use in medicine
US16/759,952 US11447548B2 (en) 2017-10-31 2018-10-31 Immunotoxins, formulations thereof and their use in medicine
US17/816,550 US12435138B2 (en) 2017-10-31 2022-08-01 Immunotoxins, formulations thereof and their use in medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1717966.4A GB201717966D0 (en) 2017-10-31 2017-10-31 Immunotoxins, formulations thereof and their use in medicine

Publications (1)

Publication Number Publication Date
GB201717966D0 true GB201717966D0 (en) 2017-12-13

Family

ID=60580274

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1717966.4A Ceased GB201717966D0 (en) 2017-10-31 2017-10-31 Immunotoxins, formulations thereof and their use in medicine

Country Status (8)

Country Link
US (2) US11447548B2 (https=)
EP (1) EP3703748A1 (https=)
JP (1) JP7482343B2 (https=)
CN (1) CN111629753B (https=)
AU (1) AU2018357984B2 (https=)
CA (1) CA3080873A1 (https=)
GB (1) GB201717966D0 (https=)
WO (1) WO2019086534A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717966D0 (en) 2017-10-31 2017-12-13 Xenikos Bv Immunotoxins, formulations thereof and their use in medicine
KR20230117189A (ko) * 2020-12-02 2023-08-07 맵웰 (상하이) 바이오사이언스 컴퍼니, 리미티드 항-인간 b7-h3 항체 및 이의 응용
CN112992266B (zh) * 2021-02-05 2021-09-21 深圳裕康医学检验实验室 一种评估肿瘤免疫耗竭状态的方法、装置和存储介质
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
KR20260016952A (ko) 2023-05-23 2026-02-04 사나 바이오테크놀로지, 인크. 탠덤 퓨소젠 및 관련 지질 입자
CN121368604A (zh) * 2023-05-30 2026-01-20 菲利克斯有限公司 用于治疗慢性炎性和自身免疫性疾病的方法和手段
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025091264A1 (zh) * 2023-10-31 2025-05-08 成都维瑾柏鳌生物医药科技有限公司 一种药物组合物用于制备治疗gvhd的药物的应用
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808705A (en) * 1986-12-19 1989-02-28 Cetus Corporation Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor
US4975184A (en) 1988-01-15 1990-12-04 Henry Filters, Inc. Horizontal removable pump for filtration systems
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6372217B1 (en) 1997-06-03 2002-04-16 Regents Of The University Of Minnesota Methods for the treatment of CD7+ viral infection with TXU-7-PAP
EP0945139A1 (en) 1998-03-23 1999-09-29 Katholieke Universiteit Nijmegen Methods and means for the treatment of immune related diseases such as Graft vs. Host disease
US20060051355A1 (en) * 1998-03-23 2006-03-09 Van Oosterhout Ypke V Methods and means for the treatment of immune-related diseases
DE602004030811D1 (de) * 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
MX2008013508A (es) 2006-04-21 2008-10-31 Novartis Ag Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
US20080233128A1 (en) 2006-11-02 2008-09-25 Werner Krause Treatment of Viral Infections
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
JP2010530895A (ja) 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
US20130115232A1 (en) 2011-10-03 2013-05-09 Fred Hutchinson Cancer Research Center Methods for detecting graft-versus-host disease
BR112015027764A2 (pt) * 2013-05-02 2017-08-29 Mabxience S A Formulações alternativas para os polipeptídeos de fusão de tnfr: fc
GB201717966D0 (en) 2017-10-31 2017-12-13 Xenikos Bv Immunotoxins, formulations thereof and their use in medicine

Also Published As

Publication number Publication date
AU2018357984B2 (en) 2025-08-14
JP2021501214A (ja) 2021-01-14
EP3703748A1 (en) 2020-09-09
US11447548B2 (en) 2022-09-20
CA3080873A1 (en) 2019-05-09
AU2018357984A1 (en) 2020-06-18
US12435138B2 (en) 2025-10-07
US20200407443A1 (en) 2020-12-31
US20240150463A1 (en) 2024-05-09
WO2019086534A1 (en) 2019-05-09
CN111629753B (zh) 2024-05-03
JP7482343B2 (ja) 2024-05-14
AU2018357984A2 (en) 2020-06-25
CN111629753A (zh) 2020-09-04

Similar Documents

Publication Publication Date Title
GB201717966D0 (en) Immunotoxins, formulations thereof and their use in medicine
ZA202003833B (en) Conjugates and preparation and use thereof
GB2588506B (en) Psilocybin polymorphic form A, formulations and use in medicine
IL268011B1 (en) Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
IL250711A0 (en) Conjugates containing cell-binding agents and cytotoxic agents
IL275208A (en) Hsp90-targeting conjugates and formulations thereof
SG11202003320SA (en) Dihydropyrimidine compounds and uses thereof in medicine
ZA201900470B (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
IL275190A (en) Anti-CD22 antibody-maytensin conjugates, combinations and methods of using them
EP3324967A4 (en) PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
PT3638251T (pt) Formulações de gel de bifosfocina e suas utilizações
SG11202004529XA (en) Transformed human cell and use thereof
PT3544637T (pt) Conjugados omv-antigénio nativos e sua utilização
GB201604213D0 (en) Drug combination and its use in therapy
SG11201803025VA (en) Compositions comprising vitamins and their use
ZA201908091B (en) Indole-formamide derivative, preparation method therefor and use thereof in medicine
IL268583A (en) Preparations and methods for use on the skin
EP3534961C0 (en) Stable aqueous injection formulations of capsaicin and their medical uses
GB201710322D0 (en) Improvements in drug delivery
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
SG11201906132UA (en) Insoluble complex or solvate thereof, pharmaceutical composition and use thereof
EP3497080A4 (en) PHARMACEUTICAL FORMULATIONS AND THEIR USE
IL274785A (en) Combined products containing dicycloplatin, their preparation and use
ZA202000959B (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
PL3478260T3 (pl) Kompozycja do pielęgnacji skóry i jej zastosowanie

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)